FDA Determines Regulatory Review Period for Arcapta Neohaler Patent Extension

Summary

The U.S. Food and Drug Administration (FDA) has officially confirmed the regulatory review period for the patent extension of Arcapta Neohaler, a human drug product, following a submission to the U.S. Patent and Trademark Office (USPTO).